FY2Q19 royalty revenue was $39.6M, down from $69.9M in FY1Q19 (Oct-Dec 2018). ENTA’s royalty rate from ABBV resets to the lowest tier at the start of each calendar year, so ENTA’s fiscal 2Q (Jan-Mar) will always have the lowest royalty tier for a given fiscal year.
(The royalty tiers applicable to the 50% Glecaprevir component of Mavyret are shown in #msg-142808661.)
ENTA’s cash balance at 3/31/19 was $387M.
FY2Q19 GAAP EPS was $0.20, due to a tax benefit.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.